DS0404 - Innovation biomédicale

Protease-activated Receptor-2 and its agonist serine proteases in idiopathic pulmonary fibrosis – PARIS-IPF

Submission summary

Pulmonary fibrosis constitutes the end-stage of a broad range of heterogeneous diseases characterized by the destruction of pulmonary parenchyma and extracellular matrix deposition in the interstitial and alveolar spaces. Idiopathic pulmonary fibrosis (IPF) is the most frequent fibrotic diffuse parenchymal lung disease. Its prognosis is devastating, and there are currently no therapeutic options available. By contrast, in cryptogenic organizing pneumonia (COP), fibrosis is reversible spontaneously or under corticosteroids treatment. We recently showed that protease-activated receptor (PAR)-2, a cell surface receptor activated by proteolytic cleavage, is instrumental in pulmonary fibrosis. PAR-2 belongs to the superfamily ofa G-protein coupled receptors (GPCR). Its activation by proteolytic cleavage induces transmembrane signaling to intracellular G proteins linked to its COOH, intracellular extremity. The activated G proteins in turn impact on a substantial network of signaling pathways with functional consequences are of crucial importance in pathophysiology. In mammals, only a finite number of serine proteases (agonists) is able to activate PAR-2. Based on our data, showing a crucial role for PAR-2 in the progression of pulmonary fibrosis, we hypothesize that targeting PAR-2, the majpor endogenous PAR-2 activating proteases, and/or the downstream signaling pathways subsequent to PAR-2 activation will limit pulmonary fibrosis. In the current PARIS-IPF proposal, we propose to address this question by employing integrated approaches, ranging from analysis of human material to cell and animal models. In patient material, we will identify and compare the major endogenous PAR-2 activating proteases in IPF and COP. We will characterize their action ex vivo and in vitro. Using high throughput technology based on peptide kinome array, we propose to establish the kinome profile of the major PAR-2 activating proteases on normal and fibrotic fibroblasts, to validate their importance ex vivo in IPF and COP, and to elucidate the involvement of PAR-2 in the signaling pathways activated. Finally, we will assess the effect of genetic and pharmacological modulation of the targets identified in a murine model of pulmonary fibrosis. Identifying the common and divergent mechanisms underlying irreversible or reversible fibrosis in IPF of COP respectively will provide important insights and potential therapeutic targets which could be used to treat IPF.

Project coordination

Keren Borensztajn (INSERM UMR 1152)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

INSERM INSERM UMR 1152
UMR_S933 INSERM INSERM DR P6

Help of the ANR 250,099 euros
Beginning and duration of the scientific project: December 2014 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter